iShares NASDAQ US Biotechnology UCITS ETF (LON:BTEC)

London · Delayed Price · Currency is GBP · Price in USD

10.06

+0.07 (0.73%)

Aug 12, 2026, 4:55 PM GMT

53.99% (1Y)

Assets	782.39M
Expense Ratio	0.35%
PE Ratio	24.86
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+54.00%

Volume	166,441
Open	9.99
Previous Close	9.99
Day's Range	9.90 - 10.06
52-Week Low	6.47
52-Week High	10.06
Beta	0.57
Holdings	261
Inception Date	Oct 19, 2017

About BTEC

iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States. It seeks to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sector. The fund invests in the stocks of companies across all market capitalizations. It seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing representative sampling methodology. iShares NASDAQ US Biotechnology UCITS ETF was formed on October 19, 2017 and is domiciled in Ireland.

Asset Class Equity

Category Health Care

Region North America

Stock Exchange London Stock Exchange

Ticker Symbol BTEC

Provider iShares

Index Tracked NASDAQ / Biotechnology

Performance

BTEC had a total return of 54.00% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.51%.

Top 10 Holdings

41.24% of assets

Name	Symbol	Weight
Amgen Inc.	AMGN	8.01%
Vertex Pharmaceuticals Incorporated	VRTX	8.00%
Gilead Sciences, Inc.	GILD	7.36%
Regeneron Pharmaceuticals, Inc.	REGN	4.90%
Revolution Medicines, Inc.	RVMD	2.78%
Alnylam Pharmaceuticals, Inc.	ALNY	2.51%
Biogen Inc.	BIIB	2.14%
Illumina, Inc.	ILMN	1.98%
Royalty Pharma plc	RPRX	1.81%
Roivant Sciences Ltd.	ROIV	1.74%

View More Holdings